共 14 条
[2]
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
[J].
PHARMACOGENETICS,
1995, 5 (06)
:358-363
[3]
DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594
[4]
DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
[5]
Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans
[J].
PHARMACOGENETICS,
1996, 6 (04)
:357-360
[6]
Ferguson RJ, 1998, J PHARMACOL EXP THER, V284, P356
[7]
BIOCHEMISTRY AND MOLECULAR-BIOLOGY OF THE HUMAN CYP2C SUBFAMILY
[J].
PHARMACOGENETICS,
1994, 4 (06)
:285-299
[8]
Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism
[J].
CYTOCHROME P450, PT B,
1996, 272
:210-218
[9]
Ibeanu GC, 1998, J PHARMACOL EXP THER, V286, P1490
[10]
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians
[J].
PHARMACOGENETICS,
1998, 8 (02)
:129-135